APIs global business developments
|
|
- Shon McDaniel
- 5 years ago
- Views:
Transcription
1 APIs global business developments Dr Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President & CEO, Euticals S.p.A., Italy EFCG Press Conference, 13th October 2015, CPhI Madrid
2 Market outlook
3 Features of the European API manufacturers High level of competence in fine chemistry Employ a range of skilled, qualified & experienced staff for: Early assessment of market opportunities All technical (incl. ESHQ) management requirements Handling Intellectual Property Rights (e.g., patent issues) Production compliance with Good Manufacturing Practices on the basis of inspections performed by Regulatory Authorities
4 Where do the European manufacturers stand? APIs market is increasingly a global business, integrated in the supply chain; Manufacturers of APIs give more value to their production towards the dosage form; Companies are increasing their size; Manufacturers in new countries - Turkey, E-Europe, Middle-East - put more pressure on the market; Opportunities and challenges of selling APIs to BRICs countries. A global market needs a global strategy
5 Current status of the APIs market APIs Global APIs merchant market = 43.0 billion USD of which European APIs production=12.0 billion USD Italian market share APIs worldwide: 11% Activities of European Manufacturing: 50% custom manufacturing 50% generic medicines
6 APIs demand worldwide* Worlwide demand for APIs 84 billion USD - of which 41 captive and 43 merchant Merchant demand 43 billion USD - of which 32 catalogue and 11 custom made Merchant demand broken down by geographical area 43 billion USD, of which: 12.5 North America 6.8 Latin America 11,5 European Union 2.7 Japan 9.1 Rest of the world * Source: Arthur D Little
7 Current APIs market outlook is positive Big-Pharma companies are returning to Europe for their APIs supplies Chinese and Indian Authorities require more engagement on the environment and safety from APIs manufacturers; Regulatory aspects will be important not only for the «regulated» countries (Europe, USA, Japan) but also for emerging countries, i.e.: Brazil, Mexico Asian manufacturers often buy European APIs to export their dosage forms to the USA; Indian and Chinese domestic markets are becoming interesting for European manufacturers.
8 Regulatory issues and their impact on the market
9 Legislations affecting APIs Global Business Developments In Europe: Falsified Medicines Directive (FMD), 2011/62/EU Came in to force on 2 nd July, 2013 In the USA: FDASIA and Generic Drug User Fee Act (GDUFA) Came into force on 1 st October, 2012
10 The Falsified Medicines Directive (FMD) 2011/62/EU Current Directive covering human medicines does NOT ensure that the APIs used in EU comply with European GMP wherever they are made; About 70% of all APIs sold in EU now come from non-eu sites; The use of many non-eu API sites is dependent on industry selfevaluation and open to corrupt practices; DG Sante/EMA have been vigilant in their monitoring of Written Confirmations and have taken action to stop importation, for example from India; Mandatory inspections of EU API sites are performed by EU Regulatory Authorities but there are no mandatory inspections of non-eu API sites; All EU countries have transposed the FMD into national law; EFCG members have picked up new business as a consequence of FMD and flight to quality by MAHs.
11 EFCG Proposals: What still needs to happen? Stricter enforcement by EU authorities and tough sanctions to punish offenders; Better training of inspectors to detect falsification and fraud; Include mandatory inspections in the law - paid for by industry if needed (cf. GDUFA/USA) - or arrange Mutual Recognition Agreements with those countries with EU GMP standards.
12 GDUFA - Generic Drug User Fee Amendments GDUFA I will expire in September 2017; Talks around GDUFA II started with the US FDA who have called for input from a user perspective; The EU fine chemicals industry (EFCG and APIC) has been invited to take part in the discussions with the FDA, along with its US counterparts; We are gathering feedback from members in the EU and the US on their experience to share with the FDA; A crucial part of these talks are the DMF fees which have doubled since 2013 due to the decreasing number of DMFs; FDA reactions are still too slow; No EFCG members are on the FDA list of companies who have not paid their fees.
13 EFCG Proposals: Goals of GDUFA II Industry wishes: to enter into GDUFA II in order to accelerate approval of generic drugs, and ensure a more level playing field. their ANDAs and DMFs to be of higher quality filings thanks to a better dialogue with the FDA
14 EU-US Transatlantic Trade & Investment Partnership (TTIP) Progress so far TTIP aims not only on cutting tariffs, but also addressing barriers behind the customs border, i.e. differences in technical regulations, standards and approval procedures; Progress is very slow and civil society / NGOs severely critical; Bilateral trade pact could be completed by next year; Strong possibility however that not all regulatory sectors under negotiation could achieve a final agreement; The missing chapters include talks in the field of regulatory cooperation on chemicals, cosmetics, pesticides amongst others: Other sensitive topics like common rules for energy and raw materials or intellectual property are still not at the negotiation stage discussions could continue in those areas after a deal is signed
15 EU-US Transatlantic Trade & Investment Partnership (TTIP) the Industry s position At the onset of the negotiations, EFCG, APIC & SOCMA filed a proposal with both the EU and US government negotiators on MRAs for GMP Inspections; A letter was sent to DG Sante, EMA, DG Trade in 2013, calling for the Pursuit of a Mutual Recognition Agreement on Good Manufacturing Practices (GMP) Inspections; A MRA on GMP Inspections between the EU and US will have an immediate positive impact on the resources of the regulatory agencies, the European Medicines Agency (EMA), National Competent Authorities (NCAs) of the EU, the Food and Drug Administration (FDA), and on the industry; The resource savings for regulators should allow for the agencies to work together to identify high-risk sites in need of inspection, including in third countries, and to ensure resources are committed to addressing this need.
16 Impact of these legislations on the market FMD: allowed companies to gain new customers who look for reliable, long-term suppliers; GDUFA: has clearly affected EBIT but has also created barriers to low-quality imports.
17 EFCG: achievements and future outlook
18 EFCG achievements Regularly in contact with the FDA for GDUFA II; cooperation with EGA on common issues; A role, through CEFIC, in TTIP; Presidency of Rx-360; A role in the FMD (Falsified Medicines Directive); Regular meetings with the European Commission and EMA; Market Survey; A successful Annual Dinner; Memorandum of Understanding between EFCG and IPEC for excipients.
19 Investments in more quality compliance is paying off and attracting customers Business is picking up and outlook for the pharma supply chain is positive for the next few years Major driving forces: Customers concerns shifted from price to compliance and continuity of supply Higher demand for higher added value products EU companies offer better quality and higher reliability EU industry is launching more innovative products Return of clients, especially innovators, who previously left Europe to go shopping for their active ingredients and excipients elsewhere
20 In Conclusion Sustainability and compliance have to remain the key drivers for our business with NO compromise on quality; The trend towards outsourcing can be expected to continue to grow. This aspect could become increasingly important, allowing a positive projected evolution of drug substances demand.
21 Thank you for your attention For more information on EFCG activities please contact: Maggie Saykali EFCG Director 4 av. E. van Nieuwenhuyse B-1160 Brussels msa@cefic.be
Quality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
More informationCurrent Status and Challenges of Bilateral/Multilateral Meetings
Current Status and Challenges of Bilateral/Multilateral Meetings Junko Sato, PhD International Liaison Officer PMDA 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views and
More informationEnforcement of Intellectual Property Rights Frequently Asked Questions
EUROPEAN COMMISSION MEMO Brussels/Strasbourg, 1 July 2014 Enforcement of Intellectual Property Rights Frequently Asked Questions See also IP/14/760 I. EU Action Plan on enforcement of Intellectual Property
More informationEDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
More informationThe Trans-Pacific Partnership (TPP) as an Opportunity for Integration A WTO Perspective
The Trans-Pacific Partnership (TPP) as an Opportunity for Integration A WTO Perspective Comments by Robert B. Koopman Chief Economist, World Trade Organization Presented May 16, 2016 The Rise of the South
More informationHow can we manage the change?
Why do we need a change? Technical conditions for the free movement of goods in EU and WTO agreements. Problems in the existing legal systems and infrastructure How can we manage the change? What do we
More informationITI Comment Submission to USTR Negotiating Objectives for a U.S.-Japan Trade Agreement
ITI Comment Submission to USTR-2018-0034 Negotiating Objectives for a U.S.-Japan Trade Agreement DECEMBER 3, 2018 Introduction The Information Technology Industry Council (ITI) welcomes the opportunity
More informationWhat We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012
What We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012 What We Heard Report: The Case for Change 1 Report of What We Heard: The Case for Change Consultation
More informationIPRs and Public Health: Lessons Learned Current Challenges The Way Forward
Local Pharmaceutical Production in Africa International Conference Cape Town, 4-6 April 2011 IPRs and Public Health: Lessons Learned Current Challenges The Way Forward Roger Kampf WTO Secretariat 1 Acknowledging
More informationDRAFT. "The potential opportunities and challenges for SMEs in the context of the European Trade Policy:
DRAFT "The potential opportunities and challenges for SMEs in the context of the European Trade Policy: Brussels - June 24th, 2014 European Economic and Social Committee V. President Giuseppe Oliviero
More informationChemicals: Future Trends in Production and Use. Implications for Chemicals Management
Chemicals: Future Trends in Production and Use. Implications for Chemicals Management Michael Gribble, ICCA UNEP, DTIE, Chemicals Branch Learning Center, CSD-19 May 3, 2011 HISTORY: 10 SHORT YEARS AGO
More informationB) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:
INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is
More informationCOUNCIL OF THE EUROPEAN UNION. Brussels, 9 December 2008 (16.12) (OR. fr) 16767/08 RECH 410 COMPET 550
COUNCIL OF THE EUROPEAN UNION Brussels, 9 December 2008 (16.12) (OR. fr) 16767/08 RECH 410 COMPET 550 OUTCOME OF PROCEEDINGS of: Competitiveness Council on 1 and 2 December 2008 No. prev. doc. 16012/08
More informationAmbassador Rita Hayes
Ambassador Rita Hayes Ambassador Rita Hayes is Chair of Hayes International Advisors, LLC where she counsels industry and institutional leaders on a diverse range of economic, political and regulatory
More informationLupin Limited Annual Results FY12. Investor Presentation May being
Lupin Limited Annual Results FY12 Investor Presentation May 2012 Vision: To be an innovation led transnational company Journey over the last decade 5th largest generics player in US Gross Revenues INR
More informationEU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
More informationTurning the wheels of your success
INDUSTRIAL SERVICES Turning the wheels of your success A comprehensive package of integrated services combining traditional certification and inspection with innovative business solutions based on the
More informationICT and Innovation for Structural Change
ICT and Innovation for Structural Change Mario Castillo ALCUE NET - Latin American, Caribbean and European Union Thematic Workshop on Information and Communication Technologies Santiago, Chile 19 20 March,
More informationTapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, LONAVALA
COMBATING COUNTERFEIT DRUGS WITH PACKAGING TECHNOLOGY Tapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, 2009 -LONAVALA Content Counterfeit Medicines:
More informationGlobalization, Sustainability and Innovation
Globalization, Sustainability and Innovation Dr. David Cohen CAWP - Faculty of Forestry, UBC Prepared for the BC Forum Workshop on Innovation November 8, 2007 1 Summary Globalization yesterday, today &
More informationJoint Statement for EU-Japan Regulatory Cooperation
Joint Statement for EU-Japan Regulatory Cooperation 13 December 2016 Ⅰ.EU-Japan EPA/FTA and Regulatory Cooperation BusinessEurope and KEIDANREN have been encouraging industrial sector-to-sector dialogue
More informationManufacture of medicinal products in Italy: challenges for the Italian Medicines Agency
Manufacture of medicinal products in Italy: challenges for the Italian Medicines Agency Isabella Marta Coordinator Inspections and Certification Dept. Head Manufacturing Authorization Office Italian Medicines
More information1. Protecting the work and expressing the potential of our clients' companies
Turin, December, 2012 PRESS FOLDER 1. Protecting the work and expressing the potential of our clients' companies 2. Over a century of solid experience and steady growth 3. A network of excellence 4. Leadership
More informationAn Integrated Industrial Policy for the Globalisation Era
Ref. Ares(2014)2686331-14/08/2014 An Integrated Industrial Policy for the Globalisation Era John Farnell Director, DG Enterprise and Industry HEADING FOR 2020 sustainable inclusive smart 7 flagship initiatives
More informationAfrican Civil Society Meeting
African Civil Society Meeting Intergovernmental Working Group on Intellectual Property, Innovation and Health Topic: Considering Domestic Manufacturing Issues Nairobi Kenya 28-29 August 2007 DR W.O. WANYANGA
More informationEDUCATION ON STANDARDS DEVELOPED BY A PUBLIC INSTITUTION OF BRAZIL TO PROMOTE COMPETITIVENESS OF INDUSTRY
EDUCATION ON STANDARDS DEVELOPED BY A PUBLIC INSTITUTION OF BRAZIL TO PROMOTE COMPETITIVENESS OF INDUSTRY 8 th ICES CONFERENCE Industry Needs Standards. What Does Industry Expect from Standards Education?
More informationMedical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade
Medical Technology Association of NZ Proposed European Union/New Zealand Free Trade Agreement Submission to Ministry of Foreign Affairs & Trade February 2016 1 Introduction The Medical Technology Association
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Dr Georges France Ms Suzette Kox
More informationpeace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
More informationBrazilian industry s activities for international convergence. Walker Lahmann Director of External Trade at ABIFINA Executive Director at Eurofarma
Brazilian industry s activities for international convergence Walker Lahmann Director of External Trade at ABIFINA Executive Director at Eurofarma Mission Congregate companies, institutes and association
More informationInter-Association Task Force
Inter-Association Task Force Presentation to EMA Workshop Prevention of Drug Shortages Based on Quality and Manufacturing Issues 9 th October 2015 1 Topics for Today Background and history of task force
More informationGlobal Nonwoven Summit
ECIPE PRESENTATION» Global Nonwoven Summit Hosuk Lee-Makiyama European Centre for International Political Economy (Ecipe)! Rue Belliard 4-6 4 Brussels, Belgium tel: -3 89 35 email: hosuk.lee-makiyama@ecipe.org
More informationFood Product Standards to Support Exports
Food Product Standards to Support Exports March 14, 2018 Lusaka, Zambia Presentation Overview GMA Background Core Regulatory Principles to Support Food/Ag Exports Science-Based Standards Regulatory Coherence
More information5 th Annual Pharma IPR Conference 2016
5 th Annual Pharma IPR Conference 2016 9 11 March 2016, Mumbai DAY 1 : 9 th March 2016 Country: US 09:40 American Invents Act Updates on Americas Invents Act and current scenario of US Patent laws Implications
More informationThe ICT industry as driver for competition, investment, growth and jobs if we make the right choices
SPEECH/06/127 Viviane Reding Member of the European Commission responsible for Information Society and Media The ICT industry as driver for competition, investment, growth and jobs if we make the right
More informationThe TFG Guide: Top Countries to Export from. Your quick guide to understanding local markets when planning and exporting from abroad.
The TFG Guide: Top Countries to Export from Your quick guide to understanding local markets when planning and exporting from abroad. BRAZIL Brazil is an export hotspot, with the largest population in
More informationIN-DEPTH ASSESSMENT OF THE SITUATION (CONTRACT NO ENTR/2010/16, LOT 2) Task 6: Research, Development and Innovation in the Footwear Sector
IN-DEPTH ASSESSMENT OF THE SITUATION OF THE EUROPEAN FOOTWEAR SECTOR AND PROSPECTS FOR ITS FUTURE DEVELOPMENT (CONTRACT NO ENTR/2010/16, LOT 2) Task 6: Research, Development and Innovation in the Footwear
More informationCounterfeit, Falsified and Substandard Medicines
Meeting Summary Counterfeit, Falsified and Substandard Medicines Charles Clift Senior Research Consultant, Centre on Global Health Security December 2010 The views expressed in this document are the sole
More informationROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU.
ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU. Can you guess? How does one protect their brand? Most brands are distinct and being distinctive is the way potential users
More informationInterim Report on the Heiligendamm Process at the G8 Summit in Hokkaido Toyako 7 to 9 July 2008
Interim Report on the Heiligendamm Process at the G8 Summit in Hokkaido Toyako 7 to 9 July 2008 Prepared by the Steering Committee of the Heiligendamm Process consisting of the personal representatives
More informationHow to take advantage of China knowledge base?
How to take advantage of China knowledge base? A CEIBS-SKEMA joint research project Barcelona, November 2013. 02/12/2013 1 A changing landscape A new world order in innovation is taking hold, one in which
More informationFinal Resolution for the 6 th European Interparliamentary Space Conference (EISC), held on November 10 th and 11 th 2004
Final Resolution for the 6 th European Interparliamentary Space Conference (EISC), held on November 10 th and 11 th 2004 The 6 th European Interparliamentary Space Conference (EISC), held at the Congress
More informationIP KEY SOUTH EAST ASIA ANNUAL WORK PLAN FOR 2018
ANNUAL WORK PLAN FOR 2018 IP KEY SOUTH EAST ASIA ANNUAL WORK PLAN FOR 2018 IP Key South East Asia is an EU Project designed to support the Free Trade Agreement (FTA) talks and Intellectual Property Dialogues
More informationMonitoring R&D resource flows: Global resources and challenges
WHO informal workshop: Wellcome Trust, London 14 February 2013 Monitoring R&D resource flows: Global resources and challenges Stephen Matlin Institute of Global Health Innovation Imperial College, London
More information15890/14 MVG/cb 1 DG G 3 C
Council of the European Union Brussels, 4 December 2014 (OR. en) 15890/14 OUTCOME OF PROCEEDINGS From: To: No. prev. doc.: Subject: Council Delegations IND 354 COMPET 640 MI 930 RECH 452 ECOFIN 1069 ENV
More informationEuropean Charter for Access to Research Infrastructures - DRAFT
13 May 2014 European Charter for Access to Research Infrastructures PREAMBLE - DRAFT Research Infrastructures are at the heart of the knowledge triangle of research, education and innovation and therefore
More informationImpact of ICH Q9 and the application of Risk Management
Safeguarding public health Impact of ICH Q9 and the application of Risk Management An inspector s perspective on the impact on inspectional approaches and expectations Ian Thrussell Strategy and Development
More informationAustralia and the European Union: an agenda for cooperation
Australia and the European Union: an agenda for cooperation Australia and the European Union: an agenda for future cooperation The 1997 Joint Declaration on Relations between Australia and the European
More informationJoint - Jobs, Enterprise and Innovation. Opening Statement. Brian Hogan Marine Survey Office. Date: 21 September 2017
Joint - Jobs, Enterprise and Innovation Opening Statement Brian Hogan Marine Survey Office Date: 21 September 2017 I thank the Chairman and Committee Members for inviting me here today. The issues which
More informationPresentation. March 2007
Presentation March 2007 1 Corporate Overview 2 Corporate Overview Leading provider of research-driven packaging solutions solely-focused on pharmaceutical industry Founded in 1994 and based in Pune, India
More informationJUST SCRATCHING THE SERVICE
CONTRACT MANUFACTURING, PACKAGING & NEW EQUIPMENT TECHNOLOGY FOR THE BIOPHARM/PHARMACEUTICAL INDUSTRY OFFICIAL MEDIA SPONSOR OF W W W. P H A R M P R O. C O M V O L U M E 3 0, N U M B E R 4 M AY 2 0 1 5
More informationTrade Policy III - WTO and Case Studies
Trade Policy III - WTO and Case Studies International Trade Theory ITAM Rahul Giri (ITAM) Trade Policy III - WTO and Case Studies 1 / 19 Objective Discuss the evolution of the World Trade Organization.
More informationCanadian Health Food Association. Pre-budget consultations in advance of the 2018 budget
Canadian Health Food Association Submission to the House of Commons Standing Committee on Finance Pre-budget consultations in advance of the 2018 budget Executive Summary Every year, $7 billion is contributed
More informationScience, Technology & Innovation Indicators
Science, Technology & Innovation Indicators Adnan Badran NASIC Conference cum Workshop on Herbal Drug Development for Socio-economic Uplift in Developing World The University of Jordan, September 6-8,
More informationPatenting trends in Indian pharmaceutical industry
Annals of Library and Information Studies Vol. 64, December 2017, pp. 260-267 Patenting trends in Indian pharmaceutical industry Pratibha Gokhale a and Sudha Kannan b a Former Head, Department of Library
More informationObservations from Pharma
Observations from Pharma Indian Patent Enforcement in the Chemical Arts Gurmeet Kaur Sidhu, Senior Patent Litigation Counsel London, 26/9/11 a Novartis company The Indian Pharmaceutical sector: Overview
More informationPublication Date Reporter Pharma Boardroom 24/05/2018 Staff Reporter
Publication Date Reporter Pharma Boardroom 24/05/2018 Staff Reporter Pharma Boardroom An Exclusive Interview with Jonathan Hunt CEO, Syngene International, India. Jonathan Hunt, CEO of Syngene International,
More informationStudy of Comparative Advantages of Chinese and Indian Pharmaceutical Industries under Globalization
MANAGEMENT SCIENCE AND ENGINEERING Vol. 4, No. 4, 2010, pp. 82-86 www.cscanada.org ISSN 1913-0341 [Print] ISSN 1913-035X [Online] www.cscanada.net Study of Comparative Advantages of Chinese and Indian
More informationINDIA Market Projections and Developments
The Seventh Annual IGPA Conference INDIA Market Projections and Developments by D G Shah Secretary General Indian Pharmaceutical Alliance Prague: June 2004 1 Potential & Problems Indian Pharmaceutical
More informationIntroduction. Vehicle Suppliers Depend on a Global Network
Introduction Motor & Equipment Manufacturers Association Comments to the United States Trade Representative RE: Request for Comment on Negotiating Objectives Regarding a U.S.- European Union Trade Agreement
More informationPDA 71 Years of Connecting People, Science and Regulation
PDA 71 Years of Connecting People, Science and Regulation 1 I m happy to be here. Bom Dia. Estou feliz por estar aqui. Richard M. Johnson PDA President & CEO since 2009 38 years experience in US and International
More informationIGDRP Mission, Scope, How it works
IGDRP Mission, Scope, How it works IGDRP-EDQM Workshop Strasbourg, France 13 May 2016 Dr. Craig Simon Associate Director, Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada
More information1 st EU Dialogue on Ecodesign and New Business Models for a Circular Economy. Introduction to the COBALT project
1 st EU Dialogue on Ecodesign and New Business Models for a Circular Economy Introduction to the COBALT project Andreas Endl Institute for Managing Sustainability Vienna University of Economics and Business
More informationWhy intellectual property can be a barrier to TT
Why intellectual property can be a barrier to TT Intellectual property grant exclusive rights ( legal monopoly) Patents 20 years minimum Copyright 50 years minimum Trade secrets indefinite North-South
More informationIMI Revolutionising Europe s Pharmaceutical Industry. IMI Matters!
IMI Revolutionising Europe s Pharmaceutical Industry IMI Matters! Session in the Framework of the Event Joint Technology Initiatives Innovation in Action 4 6 October 2011 European Parliament Brussels Programme
More informationICH Q10 Pharmaceutical Quality System
Safeguarding public health ICH Q10 Pharmaceutical Quality System An EU Regulator s Perspective Presentation overview Why does Q10 exist and what were the desired outcomes Content of the Q10 step 2 document
More informationTHESIS PRESENTATION. Gabriele Goebel-Heise 5617A011-4
THESIS PRESENTATION Gabriele Goebel-Heise 5617A011-4 RESEARCH FIELD Why knowledge transfer? Why collaborate? Why communicate difficult science & research topics? Why communicate and collaborate across
More informationCER-ASEAN Integration Partnership Forum. CER-ASEAN participation in global frameworks for international recognition and harmonisation of measurement
CER-ASEAN Integration Partnership Forum CER-ASEAN participation in global frameworks for international recognition and harmonisation of measurement Dr Angela Samuel Director, International Relations Mr
More informationIntellectual Property
Intellectual Property Johnson & Johnson believes that the protection of intellectual property (IP) is essential to rewarding innovation and promoting medical advances. We are committed: to raising awareness
More informationREWE Group Detox Program
REWE Group Detox Program Status Report 2015 December 2015 Content 1. Introduction to the Detox Program Objective and Achievements REWE Group s Detox Program - Summary of Achievements The REWE Group Detox
More informationLorenza Jachia Secretary, Working Party on Regulatory Cooperation and Standardization Policies, UN Economic Commission for Europe
The UNECE Sectoral Initiative on Environments Equipment for Explosive A global legislative framework for Explosion Protection The comprehensive approach of the UNECE Model L Regulation Lorenza Jachia Secretary,
More informationthe Companies and Intellectual Property Commission of South Africa (CIPC)
organized by the Companies and Intellectual Property Commission of South Africa (CIPC) the World Intellectual Property Organization (WIPO) the International Criminal Police Organization (INTERPOL) the
More informationTERMS OF REFERENCE. Preparation of a Policymakers Handbook on E-Commerce and Digital Trade for LDCs, small states and Sub-Saharan Africa
TERMS OF REFERENCE Reference: Post Title: NBCWG0923 Preparation of a Policymakers Handbook on E-Commerce and Digital Trade for LDCs, small states and Sub-Saharan Africa Project Location: home-based with
More informationH2020 space: a yet unreleased potential for SatCom research. H2020 Space stakeholder consultation workshop, September 2016
H2020 space: a yet unreleased potential for SatCom research H2020 Space 2018-20 stakeholder consultation workshop, September 2016 The Sector is undergoing Transformation 28% ADS market share for geo satellites
More informationCOMMISSION RECOMMENDATION. of on access to and preservation of scientific information. {SWD(2012) 221 final} {SWD(2012) 222 final}
EUROPEAN COMMISSION Brussels, 17.7.2012 C(2012) 4890 final COMMISSION RECOMMENDATION of 17.7.2012 on access to and preservation of scientific information {SWD(2012) 221 final} {SWD(2012) 222 final} EN
More informationUSTR NEWS UNITED STATES TRADE REPRESENTATIVE. Washington, D.C UNITED STATES MEXICO TRADE FACT SHEET
USTR NEWS UNITED STATES TRADE REPRESENTATIVE www.ustr.gov Washington, D.C. 20508 202-395-3230 FOR IMMEDIATE RELEASE August 27, 2018 Contact: USTR Public & Media Affairs media@ustr.eop.gov UNITED STATES
More informationGovernment/Authorities Meeting on Semiconductors. Arlington, Virginia, September 29, 2011 Chairman s Summary
Government/Authorities Meeting on Semiconductors Arlington, Virginia, September 29, 2011 Chairman s Summary 1. The Government/Authorities Meeting on Semiconductors (GAMS) took place on September 29 th,
More informationSEMINAR: INTELLECTUAL PROPERTY ARRANGEMENTS: IMPLICATIONS FOR DEVELOPING COUNTRY PRODUCTIVE CAPABILITIES IN THE SUPPLY OF ESSENTIAL MEDICINES.
SEMINAR: INTELLECTUAL PROPERTY ARRANGEMENTS: IMPLICATIONS FOR DEVELOPING COUNTRY PRODUCTIVE CAPABILITIES IN THE SUPPLY OF ESSENTIAL MEDICINES Report The two-day seminar was opened by Mr. Khalil Hamdani,
More informationLegislative and Regulatory Update. Diane Bowers, CASRO President CASRO Data Collection Conference November 19, 2009
Legislative and Regulatory Update Diane Bowers, CASRO President CASRO Data Collection Conference November 19, 2009 2009 Pharma market research state and Federal Massachusetts Vermont Minnesota Proposed
More informationDraft Plan of Action Chair's Text Status 3 May 2008
Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background
More informationASEAN: A Growth Centre in the Global Economy
Bank Negara Malaysia Governor Dr. Zeti Akhtar Aziz Speech at the ASEAN SME Conference 2015 It is my pleasure to be here this afternoon to speak at this inaugural ASEAN SME Conference. This conference takes
More informationA Guide to the Mutual Recognition Agreement between the European Community and Japan
Presented to EUROPEAN COMMISSION Directorate-General for Trade A Guide to the Mutual Recognition Agreement between the European Community and Japan September 2003 Submitted by MTA Japan Co., Ltd. & Mitsubishi
More informationRecord of Discussions On Further sophistication of industrial structure as well as human resources development and R&D promotion in Thailand
Record of Discussions On Further sophistication of industrial structure as well as human resources development and R&D promotion in Thailand The Ministry of Science and Technology, The Office of the National
More informationby: J.A.M. van Balken, EFMA, Belgium and Tore K. Jenssen, Norsk Hydro ASA, Norway
EFMA S PRODUCT STEWARDSHIP PROGRAM by: J.A.M. van Balken, EFMA, Belgium and Tore K. Jenssen, Norsk Hydro ASA, Norway Introduction Mr. Chairmen, Ladies and Gentlemen. I am very happy that the organizing
More informationEnvironmental Protection Agency
Good Laboratory Management: Means compliance with the correct regulations for each individual study.. Environmental Protection Agency Established 1970 To enforce environmental protection standards Clean
More informationCounterfeit Medicines Toolkit 4. Information about the International Medical Products Anti-Counterfeiting Taskforce (IMPACT)
Counterfeit Medicines Toolkit 4. Information about the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) 1 International Collaboration: A Request of Medicine Regulatory Authorities
More informationGOVERNMENT OF ROMANIA
GOVERNMENT OF ROMANIA DEPARTMENT FOR INFRASTRUCTURE PROJECTS AND FOREIGN INVESTMENT CONCESSION OF PERIMETERS AND NEGOTIATION OF THE CONDITIONS FOR THE PROJECTS CONCERNING EXTRACTION AND EXPLOITATION OF
More informationCopernicus Evolution: Fostering Growth in the EO Downstream Services Sector
Copernicus Evolution: Fostering Growth in the EO Downstream Services Sector Summary: Copernicus is a European programme designed to meet the needs of the public sector for spacederived, geospatial information
More informationThe Internationalization of R&D in India: Opportunities and Challenges. Rajeev Anantaram National Interest Project March 2009
The Internationalization of R&D in India: Opportunities and Challenges Rajeev Anantaram National Interest Project March 2009 Context of the Paper Part of the Private Sector Advisory Group constituted by
More informationCarnegie Endowment for International Peace
Carnegie Endowment for International Peace How the U.S. and India could Collaborate to Strengthen Their Bilateral Relationship in the Pharmaceutical Sector Second Panel: Exploring the Gilead-India Licensing
More information#Renew2030. Boulevard A Reyers 80 B1030 Brussels Belgium
#Renew2030 Boulevard A Reyers 80 B1030 Brussels Belgium secretariat@orgalim.eu +32 2 206 68 83 @Orgalim_EU www.orgalim.eu SHAPING A FUTURE THAT S GOOD. Orgalim is registered under the European Union Transparency
More informationAPI hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy.
API hapis High Potency Active Pharmaceutical Ingredients High Potency Active Pharmaceutical Ingredients Innovation made. Easy. 2 High Potency Active Pharmaceutical Ingredients High potency APIs are our
More informationThe value of innovative pharmaceuticals and the potential for Vietnam. Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016
The value of innovative pharmaceuticals and the potential for Vietnam Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016 PHARMA GROUP Our priority is to ensure that Vietnamese
More informationDraft executive summaries to target groups on industrial energy efficiency and material substitution in carbonintensive
Technology Executive Committee 29 August 2017 Fifteenth meeting Bonn, Germany, 12 15 September 2017 Draft executive summaries to target groups on industrial energy efficiency and material substitution
More informationOECD Science, Technology and Industry Outlook 2008: Highlights
OECD Science, Technology and Industry Outlook 2008: Highlights Global dynamics in science, technology and innovation Investment in science, technology and innovation has benefited from strong economic
More informationMeeting CEOC Int.-IFIA, 05 October Welcome at the CEOC premises!
CEOC International Confederation of Inspection and Certification Organisations Meeting CEOC Int.-IFIA, 05 October 2010 Welcome at the CEOC premises! CEOC in Brief (1/4) Founded in 1961 and involved in
More informationNon-ferrous metals manufacturing industry: vision for the future and actions needed
Non-ferrous metals manufacturing industry: vision for the future and actions needed Laurent Bontoux, François J. Dessart www.jrc.ec.europa.eu 4 th High Level Conference EIP on Raw Materials Brussels, 1
More informationFSMA Update. Jennifer Thomas Interim Director for FSMA Operations Center for Food Safety and Applied Nutrition Food and Drug Administration May 2018
FSMA Update Jennifer Thomas Interim Director for FSMA Operations Center for Food Safety and Applied Nutrition Food and Drug Administration May 2018 Foundational Rules Regulation Final Rule Published Preventive
More informationRECOMMENDATIONS. COMMISSION RECOMMENDATION (EU) 2018/790 of 25 April 2018 on access to and preservation of scientific information
L 134/12 RECOMMDATIONS COMMISSION RECOMMDATION (EU) 2018/790 of 25 April 2018 on access to and preservation of scientific information THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning
More informationPlease send your responses by to: This consultation closes on Friday, 8 April 2016.
CONSULTATION OF STAKEHOLDERS ON POTENTIAL PRIORITIES FOR RESEARCH AND INNOVATION IN THE 2018-2020 WORK PROGRAMME OF HORIZON 2020 SOCIETAL CHALLENGE 5 'CLIMATE ACTION, ENVIRONMENT, RESOURCE EFFICIENCY AND
More information